Oleuropein in Cancer Management
Oleuropein reprograms immunosuppressive myeloid cells in cancer patients, enhancing T cell activation and overcoming therapy resistance, thus improving cancer treatment outcomes by boosting immunotherapy efficacy.
JP2026518458APending Publication Date: 2026-06-08フンダシオン ミゲル セルベート +2
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- フンダシオン ミゲル セルベート
- Filing Date
- 2024-05-28
- Publication Date
- 2026-06-08
Smart Images
Figure 2026518458000002 
Figure 2026518458000003 
Figure 2026518458000004
Abstract
The present invention provides the use of oleuropein or its derivatives in immunotherapy, particularly as an adjuvant. In particular, the present invention provides the use of oleuropein in combination with checkpoint inhibitors in the treatment of cancer. The present invention also provides combinations comprising oleuropein and checkpoint inhibitors, as well as pharmaceutical compositions and kits of parts comprising these combinations. Advantageously, oleuropein reprograms TAMCs, increasing sensitivity to cancer therapy based on checkpoint inhibitors.
Need to check novelty before this filing date? Find Prior Art